Search research articles
Contact Us
Filters
Showing results (1-10 of 87) with videos related to
Page
of 9
Sort By:
Bulletin Du Cancer
|
January 29, 2019
Jordan Gauthier
Bone Marrow Transplantation
|
July 22, 2021
Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors
Razan Mohty, Jordan Gauthier
Cancer Journal (Sudbury, Mass.)
|
March 22, 2021
Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021
Jordan Gauthier, Cameron J Turtle
Hematology/Oncology Clinics of North America
|
August 31, 2020
Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
Jordan Gauthier, David G Maloney
Current Research in Translational Medicine
|
April 8, 2018
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
Jordan Gauthier, Cameron J Turtle
Nature Reviews. Clinical Oncology
|
November 15, 2022
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL
Richard T Maziarz, Jordan Gauthier
Bone Marrow Transplantation
|
November 24, 2020
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
Vipul S Sheth, Jordan Gauthier
Bulletin Du Cancer
|
March 24, 2015
[The role of pre-transplant debulking treatment in patients undergoing allogeneic stem cell transplantation for high-risk myelodysplastic syndrome]
Jordan Gauthier, Gandhi Damaj, Ibrahim Yakoub-Agha
Bulletin Du Cancer
|
August 11, 2011
[IMiDs in hematology]
Mathieu Wémeau, Jordan Gauthier, Xavier Leleu, et al.
Expert Review of Hematology
|
April 6, 2022
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians
Eleftheria Kampouri, Carla S Walti, Jordan Gauthier, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 87) with videos related to
Sort By:
Page
of 9
Bulletin Du Cancer
|
January 29, 2019
Jordan Gauthier
Bone Marrow Transplantation
|
July 22, 2021
Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors
Razan Mohty, Jordan Gauthier
Cancer Journal (Sudbury, Mass.)
|
March 22, 2021
Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021
Jordan Gauthier, Cameron J Turtle
Hematology/Oncology Clinics of North America
|
August 31, 2020
Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
Jordan Gauthier, David G Maloney
Current Research in Translational Medicine
|
April 8, 2018
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
Jordan Gauthier, Cameron J Turtle
Nature Reviews. Clinical Oncology
|
November 15, 2022
Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL
Richard T Maziarz, Jordan Gauthier
Bone Marrow Transplantation
|
November 24, 2020
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
Vipul S Sheth, Jordan Gauthier
Bulletin Du Cancer
|
March 24, 2015
[The role of pre-transplant debulking treatment in patients undergoing allogeneic stem cell transplantation for high-risk myelodysplastic syndrome]
Jordan Gauthier, Gandhi Damaj, Ibrahim Yakoub-Agha
Bulletin Du Cancer
|
August 11, 2011
[IMiDs in hematology]
Mathieu Wémeau, Jordan Gauthier, Xavier Leleu, et al.
Expert Review of Hematology
|
April 6, 2022
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians
Eleftheria Kampouri, Carla S Walti, Jordan Gauthier, et al.
Page
of 9